In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.
Looking ahead, Mizuho (NYSE:MFG) analysts expect General Motors (NYSE:GM) to remain well-positioned as it enters 2025, due to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback